|Bid||0.00 x 1000|
|Ask||17.09 x 900|
|Day's Range||15.26 - 16.04|
|52 Week Range||14.42 - 22.91|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Last week in Psychedelics: Field Trip Begins Trading On The Nasdaq MindMed Launches Phase 1 Trials On DMT Atai Launches New "Nose-To-Brain" Drug Delivery Company Braxia Scientific Receives Funding From Canadian Government To Study Ketamine Therapy AOC's Amendment To Allow Federal Research Into Benefits Of Psychedelics Rejected By House Again Australia Launches Psychedelics Research Institute With $29 Million In Funding From Undisclosed North American Company Entheon Biomedical Corp. Closes Acqui
Field Trip Health rose in its first day on the Nasdaq, making it the latest psychedelics company to hit a big U.S. exchange.
Ronan Levy, Field Trip Health Chairman, joins Yahoo Finance to discuss the psychedelic company’s debut on the Nasdaq and the development of the psychedelics.